These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23333708)

  • 1. Assessing the performance of two dry powder inhalers in preschool children using an idealized pediatric upper airway model.
    Below A; Bickmann D; Breitkreutz J
    Int J Pharm; 2013 Feb; 444(1-2):169-74. PubMed ID: 23333708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults.
    Delvadia R; Hindle M; Longest PW; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):138-44. PubMed ID: 22947131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of dry powder inhalers with single dosed capsules in preschool children and adults using improved upper airway models.
    Lindert S; Below A; Breitkreutz J
    Pharmaceutics; 2014 Feb; 6(1):36-51. PubMed ID: 24514766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novolizer: how does it fit into inhalation therapy?
    Magnussen H
    Curr Med Res Opin; 2005; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novolizer: the new technology for the management of asthma therapy.
    Köhler D
    Curr Opin Pulm Med; 2003 Apr; 9 Suppl 1():S11-6. PubMed ID: 12974537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technological and practical challenges of dry powder inhalers and formulations.
    Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
    Adv Drug Deliv Rev; 2014 Aug; 75():18-31. PubMed ID: 24735675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-use disposable dry powder inhalers for pulmonary drug delivery.
    Friebel C; Steckel H
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1359-72. PubMed ID: 21080859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an inhalation chamber and a dry powder inhaler device for administration of pulmonary medication in animal model.
    Sinha B; Mukherjee B
    Drug Dev Ind Pharm; 2012 Feb; 38(2):171-9. PubMed ID: 21721851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation considerations for dry powder inhalers.
    Cordts E; Steckel H
    Ther Deliv; 2014 Jun; 5(6):675-89. PubMed ID: 25090281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
    Hein S; Bur M; Schaefer UF; Lehr CM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the Entrainment Geometry of a Dry Powder Inhaler: Methodology and Preliminary Results.
    Kopsch T; Murnane D; Symons D
    Pharm Res; 2016 Nov; 33(11):2668-79. PubMed ID: 27401410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization.
    Heng D; Lee SH; Ng WK; Chan HK; Kwek JW; Tan RB
    Int J Pharm; 2013 Aug; 452(1-2):194-200. PubMed ID: 23680726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
    Lähelmä S; Kirjavainen M; Kela M; Herttuainen J; Vahteristo M; Silvasti M; Ranki-Pesonen M
    Br J Clin Pharmacol; 2005 Feb; 59(2):167-73. PubMed ID: 15676038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of a novel dry powder inhaler.
    Zhang X; Ma Y; Zhang L; Zhu J; Jin F
    Int J Pharm; 2012 Jul; 431(1-2):45-52. PubMed ID: 22543053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Device factors affecting pulmonary delivery of dry powders.
    Smutney CC; Grant M; Kinsey PS
    Ther Deliv; 2013 Aug; 4(8):939-49. PubMed ID: 23919473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aerosol therapy].
    Wildhaber JH
    Schweiz Med Wochenschr; 1998 Aug; 128(33):1223-8. PubMed ID: 9757487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.